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Abstract 
INF2 is a formin protein that accelerates actin polymerization.  A common mechanism for 
formin regulation is autoinhibition, through interaction between the N-terminal diaphanous 
inhibitory domain (DID) and C-terminal diaphanous autoregulatory domain (DAD).  We recently 
showed that INF2 utilizes a variant of this mechanism which we termed ‘facilitated 
autoinhibition’, whereby a complex consisting of cyclase-associated protein (CAP) bound to 
lysine-acetylated actin (KAc-actin) is required for INF2 inhibition, in a manner requiring INF2-
DID.  De-acetylation of actin in the CAP/KAc-actin complex activates INF2.  Here, we use lysine-
to-glutamine mutations as acetyl-mimetics to map the relevant lysines on actin for INF2 
regulation, focusing on K50, K61 and K328.  Biochemically, K50Q- and K61Q-actin, when bound 
to CAP2, inhibit full-length INF2 but not INF2 lacking DID.  When not bound to CAP, these 
mutant actins polymerize similarly to WT-actin in the presence and absence of INF2, suggesting 
that the effect of the mutation is directly on INF2 regulation.  In U2OS cells, K50Q- and K61Q-
actin inhibit INF2-mediated actin polymerization when expressed at low levels.  Direct binding 
studies show that the CAP WH2 domain binds INF2-DID with sub-micromolar affinity but has 
weak affinity for actin monomers, while INF2-DAD binds CAP/K50Q-actin 5-fold better than 
CAP/WT-actin.  Actin in complex with full-length CAP2 is predominately ATP-bound.  These 
interactions suggest an inhibition model whereby CAP/KAc-actin serves as a bridge between 
INF2 DID and DAD.  In U2OS cells, INF2 is 90 and 5-fold less abundant than CAP1 and CAP2, 
respectively, suggesting that there is sufficient CAP for full INF2 inhibition. 
 
 
Significance Statement 
Tight regulation is required to control biochemical reactions in cells, so that these reactions can 
be activated precisely when and where needed.  Our work focuses on actin, a protein that 
polymerizes into filaments in at least 20 distinct processes in mammalian cells.  We have 
previously shown that a relatively minor modification on actin, lysine acetylation, is crucial for 
regulation of a specific population of actin filaments, through a protein called INF2.  Here, we 
identify key acetylated lysines that control INF2 activity.  INF2 mutations link to two human 
diseases, focal segmental glomerulosclerosis (a kidney disease) and Charcot-Marie-Tooth 
disease (a neuropathy), and our findings further the mechanistic understanding of these 
diseases.   
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Introduction 
A common mechanism for protein regulation is autoinhibition, whereby intra-molecular 
contacts inhibit the protein’s biological function.  Formin proteins are actin assembly factors.  
Several of the 15 mammalian formins are autoinhibited through interaction between the N-
terminal diaphanous inhibitory domain (DID) and the C-terminal diaphanous autoregulatory 
domain (DAD), which blocks the ability of the formin homology 2 (FH2) domain to accelerate 
actin polymerization (1, 2).  One formin, INF2, employs a variation of this mechanism.  Despite 
having both DID and DAD sequences which are necessary for INF2 regulation in cells (Figure 
1A), purified INF2 is fully active in biochemical assays.  Direct binding studies show that INF2’s 
DID/DAD interaction is at least 10-fold weaker than that of mDia1 (3, 4), providing an 
explanation for the lack of autoinhibition.  In addition, INF2’s DAD is similar to an actin-binding 
WH2 motif (5), and binds actin monomers with high affinity (6, 7).  These findings led us to 
predict that an additional protein is required to inhibit INF2 in a DID/DAD-dependent manner. 
 
We isolated a protein complex capable of inhibiting purified INF2 in a manner that requires 
INF2’s DID (8).  The complex consists of cyclase-associated protein (CAP) bound to actin itself.  
Both mammalian CAP proteins, CAP1 and CAP2, can inhibit INF2.  CAP consists of an N-terminal 
region containing an oligomerization domain (OD) and a helical folded domain (HFD), a middle 
region consisting of a WH2 motif flanked by proline-rich sequences, and a C-terminal CARP 
domain (Figure 1B).  The N-terminal OD from both budding yeast CAP and human CAP1 has 
been shown to hexamerize (9, 10), which is consistent with our results on full-length CAP2 (8).  
Two regions of CAP can bind actin monomers:  the WH2 motif and the CARP domain.  The CARP 
domain binds ADP-actin with high affinity, while the WH2 domain binds ATP-actin with lower 
affinity (11-13).  A structure of CARP/actin complex shows that dimeric CARP binds two actin 
monomers in a manner that exposes actin’s WH2 binding site (12)(Figure 1C).  CAP has multiple 
potential functions in actin dynamics, including acceleration of actin nucleotide exchange and 
enhancing cofilin-mediated depolymerization (14).  This latter function requires the HFD, that 
can bind cofilin-actin complex (15-18). 
 
A key feature of INF2 inhibition by CAP/actin complex is that lysine acetylation of the actin is 
required, as supported by the following findings (8).  First, pre-treatment of CAP/actin with 
histone deacetylase 6 (HDAC6) virtually eliminates INF2 inhibition.  Second, isolation of 
CAP/actin complex from mammalian cells treated with HDAC6 inhibitor increases both the 
amount of acetylated actin bound to CAP and the inhibitory potency of the CAP/actin complex.  
Third, transient activation of INF2 in cells causes a decrease in lysine-acetylated actin in 
CAP/actin complex on a similar time course to INF2 activation.  Fourth, HDAC6 inhibition blocks 
INF2-mediated actin polymerization in cells. 
 
Lysine acetylation of histones and other nuclear proteins has long been known to serve as an 
important regulatory mechanism for gene expression, but multiple cytoplasmic proteins are 
also known to be lysine-acetylated (19, 20), including tubulin, cortactin, and the formin mDia2 
(21-23).  Actin itself can be acetylated on multiple lysines (24, 25).  The functional significance 
of actin acetylation has not been studied extensively, with one published study suggesting that 
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acetylation of K326 or K328 in Drosophila flight muscle causes defects in morphology and 
performance (26). 
 
We address two questions in the current work.  First, which lysine(s) on actin is/are relevant for 
acetylation-mediated INF2 regulation?  Using lysine-to-glutamine mutations to mimic 
acetylation, we find that K50 and K61 are key residues whereas K328 is not.  Second, what 
interactions between CAP, lysine-acetylated actin (KAc-actin) and INF2 mediate the inhibitory 
interaction?  Two proposed mechanisms (8) are:  1) ‘facilitated autoinhibition’, whereby 
CAP/KAc-actin binds the DID/DAD complex to secure the low-affinity DID/DAD interaction; or 2) 
the ‘bridge’ model, whereby CAP/KAc-actin binds between the DID and the DAD.  Our studies 
here provide support for the bridge model (Figure 1D). 
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Results 
K-to-Q mutants of -actin retain similar polymerization properties to WT-actin 
We reasoned that lysine-to-glutamine mutations might functionally mimic acetylation at 
specific sites on actin.  Similar mutations have been used to mimic acetylation of actin (26) and 
other proteins (27-29).  Here, we examine three mutants to human -actin biochemically and in 
cells:  K50Q, K61Q, and K328Q.  These residues are surface-exposed in the filament structure, 
with K50 and K61 being in sub-domain 2, and K328 in sub-domain 3. 
 
To produce -actin amenable for biochemical tests, we used a system similar to those used 
previously (30, 31), in which actin is expressed as an N-terminal fusion with the monomer-
binding protein thymosin 4 (T4), then cleaved with chymotrypsin post-purification, resulting 
in actin with no additional amino acids.  The initial affinity purification step results in actin-T4 
without detectable free actin (SI Appendix Fig. S1A), suggesting that no endogenous actin co-
purifies.  Use of this system results in actin without other major protein bands for WT, K50Q, 
K61Q and K328Q (SI Appendix Fig. S1B).   
 
Next, we conducted tests to assess the functionality of the recombinant actins, compared to 
rabbit muscle (RSK) actin.  All recombinant actins are polymerization-competent.  By high-speed 
pelleting assay (32), less than 0.17 M actin is in the supernatant after overnight 
polymerization (Fig. 2A, SI Appendix Fig. S1C), suggesting that the critical concentrations are 
similar to RSK-actin (33).  By pyrene-actin polymerization, all actins polymerize with similar 
kinetics (Fig. 2B), with two variations.  First, WT -actin has a shorter polymerization lag than 
either RSK- actin or any of the mutants.  Second, the plateau fluorescence for all mutant actins 
is approximately 10% lower than for WT -actin or RSK- actin.  This difference in plateau likely 
represents a difference in pyrene fluorescence change rather than a difference in 
polymerization ability, given the similar critical concentrations.  We quantified polymerization 
rates of the actins by determining the time to ½ maximum polymerization (Fig. 2D), and found 
that the rates of WT, K61Q and K328Q -actin are faster than RSK-actin, whereas K50Q -actin 
is indistinguishable from RSK-actin.   
 
We also assessed the effects of INF2 on the polymerization of recombinant actins, testing both 
full-length INF2 and INF2-FFC.  The INF2 isoform used in this study is the nonCAAX variant, 
which is largely cytosolic and lacks the C-terminal prenylation site of the INF2-CAAX isoform (34, 
35).  By high-speed pelleting assay, both INF2 constructs cause a slight increase in the actin 
recovered in the supernatant (Fig. 2A, SI Appendix Fig. S1C), suggestive of a shift in critical 
concentration due to INF2’s effects on barbed end dynamics (36, 37).  The degree of this shift is 
similar for all actins tested, and is below 0.2 M.  As a control, all actin’s polymerized in the 
presence of barbed end capping protein results in a shift in supernatant actin to a value similar 
to the pointed end critical concentration (Fig. 2A, SI Appendix Fig. S1C), suggesting that capping 
protein interaction is not fundamentally affected by the mutations. 
 
By pyrene-actin assay in the presence of INF2-FFC or INF2-FL, all three actin mutants display a 
lower polymerization plateau than WT -actin or RSK-actin (Fig. 2C, SI Appendix Fig. S1D).  This 
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effect is similar to that found for actin alone, again suggesting a change in pyrene-actin 
fluorescence rather than in polymerization properties.  In terms of polymerization rate, the 
values for all mutants in the presence of INF2-FL are slightly slower than for WT -actin or for 
RSK actin (Fig. 2D). 
 
In summary, these analyses suggest that the -actins produced recombinantly have largely 
similar polymerization properties to RSK-actin, both in the absence and presence of INF2.  The 
minor differences in their polymerization rates in the presence of INF2-FL do not account for 
the effects of specific mutants on INF2-FL activity when in complex with CAP2, described next. 
 
K50Q and K61Q actin are INF2 inhibitors when in complex with CAP2 
We assessed the ability of CAP-complexed -actin mutants to inhibit actin polymerization by 
INF2-FL.  Previously, we found that purified CAP1 or CAP2 preparations from HEK293 cells, 
containing approximately equi-molar actin, were poor INF2 inhibitors.  However, CAP became a 
potent INF2 inhibitor when the bound actin (293A) was exchanged with certain types of actin 
(mouse brain or chicken skeletal muscle actin), but not with others (RSK-actin) (8).  Here, we 
used a similar approach to exchange WT- or K-to-Q -actin mutants onto CAP2.   
 
Exchange of CAP2/293A with either RSK-actin or any of the recombinantly-expressed -actins 
results in similar CAP/actin ratios (SI Appendix Fig. S2A).  We also examined the nucleotide state 
of the bound actin before and after exchange.  Purified CAP2/actin contains both ATP and ADP, 
with ATP being ~65% of the total (SI Appendix Fig. S2B).  Interestingly, the ‘mock’ exchange 
reaction, in which CAP2/actin is incubated with buffer containing 0.2 mM ATP, causes the 
ATP:ADP ratio to increase, suggesting nucleotide exchange on the bound actin.  Exchange with 
either WT- or K50Q-actin results in a similar increase in ATP:ADP ratio (Fig. S2C).   
 
We assessed the effects of exchanged CAP2/actin complexes on actin polymerization by full-
length INF2-nonCAAX in pyrene-actin assays.  At 1 M CAP, the CAP/K50Q and CAP/K61Q 
complexes display strong inhibition of INF2 activity (Fig. 3A).  In contrast, the CAP/K328Q, 
CAP/WT, CAP/RSK, and CAP/293A complexes display much less inhibition.  Concentration 
curves show that CAP/K50Q has an IC50 of 212 nM, while CAP/K61Q has an approximate IC50 of 
770 nM and does not reach an inhibition plateau at the highest concentration tested (Fig. 3B).  
The other constructs display minimal inhibition at all concentrations tested (Fig. 3B). 
 
We tested the specificity of this CAP/actin inhibition for full-length INF2 in two ways.  First, we 
examined the effects of the CAP/actin complexes on polymerization of actin alone.  At 1 M 
CAP, all complexes slightly accelerate actin polymerization (Fig. 3C), similar to our past results 
on CAP/actin complexes (8).  Next, we examined the effects of CAP/actin complexes on actin 
polymerization acceleration by INF2-FFC, which lacks the N-terminal DID (Fig. 1A).  At 1 M 
CAP, none of the complexes affect INF2-FFC activity (Fig. 3D).   
 
Finally, we asked whether increasing the percentage of K50Q-actin to WT-actin in the CAP/actin 
complex caused a progressive change in INF2 inhibition, by altering the K50Q:WT ratio in 
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exchange reactions.  Increasing the K50Q:WT percentage causes a progressive increase in INF2 
inhibition (Fig. 3E, F).  Since the amount of actin bound to CAP is not different between K50Q- 
and WT-actin exchanged CAP (Fig. S2A), this suggests that an increased proportion of Ac-actin 
bound to CAP increases inhibitory potency. 
 
These results suggest that the K50Q and K61Q actin mutants, when complexed with CAP2, act 
as potent inhibitors of INF2 activity, presumably by acting as acetylation mimics.  This inhibition 
requires INF2’s DID, suggesting that the CAP/actin complexes aid INF2 auto-inhibition.  In 
contrast, the K328Q mutant is a poor actin inhibitor. 
 
We also tried to load a previously described C-terminal construct of CAP1 (15), containing the 
WH2 motif and CARP domain, with ATP-actin.  Interestingly, while full-length CAP2 can remain 
stably bound to ATP-actin, we only obtain ~15% binding of ATP-actin to CAP1-Cterm, for RSK-
actin, WT-, or K50Q--actin (SI Appendix Fig. S2D).  This result agrees with past studies showing 
low affinity of this construct for ATP-actin (15). 
 
Acetyl-mimetic actin mutants inhibit INF2-mediated actin polymerization in cells 
To test the effect of K-to-Q mutant actins in cells, we constructed a bis-cistronic vector co-
expressing untagged -actin along with mCherry (Fig. 4A).  We transiently transfected this 
actin/mCherry vector into U2OS cells, along with a vector expressing GFP-F-tractin, an actin 
filament probe.  We then assessed cytosolic actin filament levels induced by ionomycin 
stimulation, which we and others have previously shown to be INF2-dependent (38-41).  We 
image the cells in a medial z-section, to avoid abundant basal actin structures.  In control cells 
without the actin/mCherry vector or expressing mCherry alone, ionomycin causes a transient 
increase in cytoplasmic actin filaments, as detected by an increase in filamentous GFP-Ftractin 
(SI Appendix Fig. S3A,B).  Cells expressing WT- or K328Q-actin display a similar ionomycin-
induced actin burst (Fig. 4B,C).  In contrast, cells expressing the K50Q or K61Q mutants display 
greatly reduced responses to ionomycin (Fig. 4B,C).  These results suggest that acetylation at 
K50 or K61 is sufficient for potent INF2 inhibition in cells.   
 
To test whether the actin mutants affect other types of stimulus-induced actin polymerization, 
we examined U2OS response to the mitochondrial un-coupler CCCP, which induces a rapid and 
transient actin polymerization burst around mitochondria that is INF2-independent (42).  
Expression of either WT-actin or K50Q-actin construct in U2OS cells does not affect the CCCP-
induced actin burst (Fig. 4D, SI Appendix Fig. S3C).  This result suggests that the effect of the 
K50Q mutant on ionomycin-induced actin polymerization is INF2-specific, and not an effect on 
actin polymerization in general. 
 
We conducted additional experiments to test the validity of the actin expression system.  To 
test the effect of exogenous actin expression on overall actin protein levels, we sorted 
transfected cells for low and high mCherry expression by flow cytometry, and then conducted 
western blot analysis for actin, mCherry and calnexin (loading control).  None of the 
actin/mCherry vectors cause an increase in actin:calnexin ratio, in either the low- or high-
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mCherry pools (SI Appendix Fig. S4A, B), suggesting that the level of exogenous actin is well 
below that of the total cellular actin pool.       
 
Next, we assessed the possibility that expression of actin mutants changes overall actin 
filament distribution, by analyzing fixed cells stained with FITC-phalloidin.  Visual examination 
of either the basal region or a medial region show no major differences in FITC staining 
between transfected and un-transfected cells for any of the constructs (SI Appendix Fig. S4C).  
We also examined the levels of GFP-F-tractin and mCherry expressed in the cells used for live-
cell analysis of ionomycin response.  None of the constructs displayed aberrantly high 
expression of F-tractin or mCherry (SI Appendix Fig. S4D,E), suggesting that effects of the K50Q 
and K61Q constructs are not due to over-expression of these constructs.  In fact, the levels of 
mCherry expression in the K50Q mutant-expressing cells were consistently lower than in the 
other samples.  Finally, we examined the effect of F-tractin expression level on the ionomycin-
induced actin burst response, and found a linear relationship between initial F-tractin intensity 
and peak ionomycin-induced F-tractin intensity (SI Appendix Fig. S4F).  Since F-tractin levels are 
similar between the constructs tested, this result shows that the system is not saturated for F-
tractin.   
 
Our overall conclusion is that two actin mutants, K50Q and K61Q, significantly compromise 
INF2 activation in U2OS cells.  In contrast, K328Q has little effect on INF2 activation. 
 
Direct binding studies suggest that CAP-WH2 domain binds INF2-DID, while CAP/Ac-actin binds 
INF2-DAD 
We used fluorescence anisotropy to examine binding between the WH2 motifs of CAP1 or CAP2 
(SI Appendix Fig. S5A) with both WT and K50Q -actin monomers, as well as with INF2’s DID-
containing N-terminal region.  In parallel, we conducted similar binding studies for INF2’s DAD-
containing C-terminal region.  A schematic of the interactions tested here is in Figure 5A. 
 
Similar to past results using muscle actin (6, 7), INF2-Cterm binds both WT-actin and K50Q-actin 
with Kd
app of 78 nM and 63 nM, respectively (Fig. 5B).  In contrast, neither CAP1-WH2 nor CAP2-
WH2 bind RSK-actin or WT-actin with sufficient affinity to determine an accurate dissociation 
constant, with estimated Kd
app of 10, 16, 25, and 22 M respectively (Fig. 5C, SI Appendix Fig. 
S5B).  Interestingly, the WH2 motifs from both CAP proteins display no detectable binding to 
K50Q-actin (Fig. 5C, SI Appendix Fig. S5B).   
 
We previously showed that INF2-Cterm displays moderate affinity for CAP/actin (8).  To test 
whether actin acetylation affects this interaction, we conducted anisotropy experiments for 
INF2-Cterm with either CAP/WT-actin or CAP/K50Q-actin.  Interestingly, the affinity increases 
~5-fold with K50Q-actin (Fig. 5D, Kd
app 1066 nM for CAP/WT-actin and 211 nM for CAP/K50Q-
actin). 
 
Finally, we tested the possibility that CAP-WH2 might interact with INF2-DID.  Interestingly, 
both CAP1-WH2 and CAP2-WH2 display significant affinity for the N-terminal region of INF2 
(Fig. 5E, SI Appendix Fig. S5C), with Kd
app of 480 nM and 390 nM, respectively.  We have 
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previously shown that the A149D mutation in INF2-DID, which is analogous to a mutant that 
disrupts DID/DAD binding in mDia1, causes constitutive activation of INF2 in cells (6, 8).  
Interestingly, both CAP1-WH2 and CAP2-WH2 display reduced affinity for A149D-mutant INF2-
DID (Kd
app of 1723 nM and 1148 nM, respectively).  In contrast, INF2-Cterm displays low affinity 
for both WT- and A419D-INF2-Nterm (estimated Kd
app of 22 and 18 M respectively, Fig. 5F), 
similar to previous findings (3).   
 
CAP1 and CAP2 are present in excess over INF2 in U2OS cells 
We used quantitative western blotting to determine levels of CAP1, CAP2 and INF2 in U2OS 
cells (SI Appendix Fig. 6).  We first raised polyclonal antibodies against bacterially-expressed 
human CAP1 and CAP2, and determined the specificity of the antibodies against their 
respective CAP-GFP purified from HEK293 cells.  Anti-CAP2 displays no observable cross-
reactivity to CAP1 at the protein amounts tested, whereas anti-CAP1 displays weak CAP2 cross-
reactivity, at ~30-fold less than CAP1 from band densities.  Interestingly, the band of untagged 
CAP in both the CAP1-GFP and CAP2-GFP preparations appears to be predominately CAP1, since 
it is detected by anti-CAP1 but not anti-CAP2. 
 
We determined a linear range of detection for purified CAP1-GFP, CAP2-GFP, and GFP-INF2-
nonCAAX, using anti-INF2 raised previously (35) in the presence of fixed concentrations of U2OS 
cell extract.  We then used U2OS extracts of well-defined cell and protein concentrations to 
analyze CAP1, CAP2, and INF2 signal intensity in the linear detection range.  Both CAP1-GFP and 
CAP2-GFP display doublet bands by western, and we used both bands for quantification.  From 
extracts, CAP2 runs as a doublet, and we used the lower band for quantification. 
 
U20S cells contain 7.95x106, 4.44x105, and 8.79x104 molecules/cell of CAP1, CAP2 and INF2, 
respectively (Table 1).  From the same extract, the total actin concentration is 1.96x108 
molecules/cell (Table 1), similar to that determined previously (43).  To estimate cytoplasmic 
concentrations, we used cell and organelle volumes determined from an in-depth lattice light 
sheet study of Cos7 cells (44), with the resulting cytoplasmic volume (3.14 pL) approximating 
that determined for NIH 3T3 cells (2.26 pL) using different methods (45).  These estimates are 
provided in Table 1.  Overall, CAP1 and CAP2 are approximately 90- and 5-fold more abundant 
than INF2 in U2OS cells. 
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Discussion 
We make the following advances concerning the mechanism of INF2 regulation by CAP/KAc-
actin.  First, we show that acetyl-mimetic mutants of two residues, K50 and K61, confer 
inhibitory activity to -actin when coupled to CAP, both in biochemical assays and in cells.  
Second, we provide evidence that the DID of INF2 does not engage in an autoinhibitory 
interaction with its DAD but binds the WH2 of CAP, while INF2-DAD binds at another site on the 
CAP/KAc-actin complex in a manner that is influenced by actin acetylation.  These findings 
support a bridge model for INF2 inhibition (Figure 1D). 
 
We purified recombinant -actin as well as three mutants, K50Q, K61Q and K328Q, for 
biochemical assays.  The positions of these three residues suggested that the mutations would 
not affect the basic polymerization properties of actin.  Indeed, the critical concentrations of all 
-actins made here appear similar to RSK-actin, while there are minor differences in 
polymerization kinetics.  Most importantly, all of the mutant actins are efficiently polymerized 
by INF2, suggesting that acetylated actin alone is not an INF2 inhibitor.   
 
When in complex with CAP2, two acetyl-mimetic mutants (K50Q and K61Q) inhibit INF2 with 
significantly higher potency than WT-actin.  The inhibition potency of CAP2/K50Q-actin (IC50 of 
212 nM) is comparable to that of the inhibitory CAP/actin complexes we identified previously 
(CAP2/brain actin and CAP2/chicken muscle actin, IC50s of 54 and 254 nM, respectively).  
CAP2/K61Q-actin is not as potent, with an estimated IC50 of 772 nM.  In contrast, CAP2/K328Q-
actin displays negligible INF2 inhibitory activity.   
 
These results suggest that acetylation in sub-domain 2 of the actin monomer is key to INF2 
inhibition.  K50 is in the “D-loop”, which is unstructured in many actin structures, whereas K61 
is in a helical region.  Both residues face away from CAP in the CARP/actin crystal structure 
(Figure 1C).  Intriguingly, this region of sub-domain 2 gets pulled back towards CARP (12), 
further exposing these residues (Figure 1C). 
 
This study represents the first mechanistic evaluation of actin acetylation effects and, as such, 
raises interesting new questions.  First, might dual acetylation of K50 and K61 increase INF2 
inhibition, as suggested for K326 and K328 acetylation in Drosophila flight muscle (26)? Second, 
how does actin acetylation interface with other actin post-translational modifications?  
Interestingly, K50 and K61 reside near M44 and M47, which are substrates for MICAL-mediated 
oxidation (50).  Third, do other acetylated lysines play roles in INF2 regulation?  We had 
previously identified several other acetylated lysines (8), and a number of additional acetylation 
sites have been identified in proteomic screens (24).   
 
As an aside, both INF2-full length and INF2-FFC do increase the apparent critical concentration 
slightly for all actins tested.  This change might reflect INF2’s severing/depolymerization ability 
(7, 36, 37), or the relative effects of the FH2 on on-rate and off-rate at the barbed end, which 
varies between formins (46-49).  We have previously found that INF2-FFC slows barbed end 
elongation by ~60% (37). 
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Actin binding by full-length CAP reveals several interesting features.  First, full-length CAP2 can 
bind ATP-actin with high affinity, since significant ATP-actin remains on CAP after extensive 
purification in nucleotide-free buffer.  Given that previous results have shown the CARP domain 
to have much higher affinity for ADP-actin than for ATP-actin (11-13), this result is surprising, 
and suggests that the full-length protein varies somewhat.  The WH2 motif is not to be the 
major ATP-actin binder, since it has low affinity ATP-actin (Figure 5).  However, the situation 
might be different in the context of the full-length CAP.  Second, full-length CAP2 can allow 
nucleotide exchange on the bound actin, without causing its release.  Third, ATP-actin can 
replace bound actin on CAP2.  In view of the fact that the ‘mock’ exchange reactions do not 
result in loss of actin from CAP2, this result presents interesting questions as to how the 
exchange takes place. 
 
This paper also provides new insights into the relevant interactions regulating INF2 activity.  
Two pieces of evidence suggest that INF2-DAD is binding primarily to actin in the CAP/actin 
complex, in a manner that is enhanced by actin acetylation.  First, INF2-Cterm binds actin 
monomers with much higher affinity than it binds INF2-DID.  While INF2’s DID/DAD interaction 
would be significantly enhanced by their presence in the same polypeptide, the high affinity of 
INF2-DAD for actin disfavors DID/DAD interaction even in the full-length protein (6).  Second, 
INF2-Cterm binds CAP/K50Q-actin with 5-fold higher affinity than CAP/WT-actin.  We propose 
that INF2-DAD binds actin in an analogous manner to established WH2/actin interactions (5).  
We also hypothesize that the acetylated actin residues are not part of the binding interface, but 
that their acetylation results in conformational changes that enhance WH2 binding.  Given their 
relative affinities for DAD, free actin monomers would be expected to out-compete CAP/K50Q-
actin.  However, the high concentration of profilin in mammalian cells reduces free actin levels 
substantially.   
 
Our data also suggest that the relevant interaction of INF2-DID is with CAP-WH2, based on the 
following data.  First, both CAP1-WH2 and CAP2-WH2 bind the DID-containing INF2-Nterm with 
sub-micromolar affinity, which is appreciably tighter than INF2’s own DID/DAD interaction.  
Second, neither WH2 motif binds actin monomers with appreciable affinity, and binding is 
undetectable to K50Q-actin.  While it has been shown that actin monomer binding by the WH2 
motif might be relevant for CAP’s other biochemical functions (11-13), the lack of binding to 
K50Q-actin makes it unlikely to interact with actin in INF2 regulation. 
 
Based on these results, we propose that CAP/KAc-actin inhibits INF2 by serving as a bridge 
between INF2-DID and INF2-DAD/WH2 (Figure 1D), rather than as a facilitator of INF2’s 
DID/DAD interaction.  KAc-actin is likely bound to CAP’s CARP domain, since the HFD appears to 
only bind cofilin-bound actin monomers (15-18).  One interesting structural feature is that 
CAP’s CARP forms a back-to-back dimer, with actins on the outer surfaces (12), so that a 2:2 
complex of CARP with KAc-actin might inhibit one INF2 dimer (8).  Another interesting feature is 
that the N-terminal region of CAP has been shown to hexamerize (9, 10).  Our previous studies 
suggested that both purified human CAP1 and CAP2 form hexameric complexes, raising the 
possibility that three INF2 dimers could be inhibited by one CAP hexamer bound to six 
acetylated actins.  However, our fractionation results from mouse brain suggest that smaller 
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CAP-containing complexes might also exist (8), so the stoichiometry of the inhibitory complex in 
cells remains to be determined.   
 
In our model, INF2 activation would occur through HDAC6-mediated de-acetylation of lysines in 
sub-domain 2, which would weaken the affinity of INF2-DAD for actin in the CAP/actin complex.  
Our proposal that the acetylated lysines do not form part of the DAD-binding interface would 
allow for HDAC6 access to the acetylated groups, resulting in the rapid stimulus-induced INF2 
activation that we observe in cells (8, 41).  The fate of the CAP/actin complex after 
deacetylation is interesting to consider.  The complex could remain bound to INF2-DID, and 
influence INF2’s activity on actin in a positive manner, possibly by directing ATP-bound actin 
monomers to FH1-bound profilin. 
 
Our work here focuses on the INF2-nonCAAX splice variant, which is predominantly cytosolic.  It 
is likely, however, that the ER-bound INF2-CAAX variant is subject to similar regulation because 
it is strongly inhibited in cells, similar to INF2-nonCAAX (6, 38, 40, 41).  In addition, HDAC6 
inhibition blocks the mitochondrial calcium increase that occurs downstream of both histamine 
and ionomycin stimulation in U2OS cells (8), an effect dependent upon INF2-CAAX (41).   
 
Finally, we show that the cellular concentrations of CAP1 and CAP2 are in excess to that of INF2.  
These results suggest that CAP is in sufficient excess to inhibit INF2, in addition to its other 
cellular roles (14).  CAP1 is nearly 20-fold more abundant than CAP2 in U2OS cells, so is likely 
the primary regulator of INF2 in this cell type.  One question is how CAP’s role in INF2 
regulation is balanced with its other cellular roles.  In addition, it will be important to determine 
the differential roles of CAP1 and CAP2 in INF2 regulation, as well as their own regulatory 
mechanisms.  CAP1 has known phosphorylation sites just N-terminal to the CARP domain (51) 
that have been shown to influence its cellular effects, and CAP2 has sites that are possibly 
analogous.  It is interesting that CAP2 consistently runs as a doublet, both from cell lysates and 
as the purified protein, possibly due to post-translational modification.    
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Materials and methods 
Plasmids 
Human INF2 full-length nonCAAX and CAP2 constructs described previously (8).  For actin 
purification construct, the entire human wild type--actin-thymosin β4-6xHis tag cDNA 
(including stop codon 3’ to 6xHis) was PCR amplified from an expression plasmid designed for 
insect cells (gift from Kathy Trybus) and subcloned into Xho1/EcoR1 sites of eGFP-N1 vector 
(Clonetech Inc).  For bis-cistronic -actin expression plasmid, human wildtype--actin alone was 
PCR amplified from the Trybus -actin expression plasmid and cloned into Xho1/EcoR1 sites of 
PICherryNeo (Addgene #52119).  For bacterial expression, CAP1 and CAP2 WH2 motifs (amino 
acid 247-292 and 254-297, respectively) were PCR amplified from human CAP1 and CAP2 cDNA 
(NovoPro 710829-5 (NM-006367) and 710470-11 (NM-006366)) and subcloned into 
BamH1/EcoR1 sites of pGEX-KT (52) with HRV3C protease site introduced between GST tag and 
WH2 motif.  Human INF2-CAAX C-term (amino acids 941-1249) and DID-containing construct 
(amino acids 1-420) described previously (6). GFP-F-tractin plasmid described previously (41).   
 
Protein expression, purification, and labeling 
Rabbit skeletal muscle actin purified from acetone powder (53). Rabbit muscle actin labeled 
with pyrenyliodoacetamide (54). Both labeled and unlabeled actin gel-filtered on Superdex 75 
16/60 (GE Biosciences) and stored in G-buffer (2 mM Tris-HCl pH 8, 0.5 mM DTT, 0.2 mM ATP, 
0.1 mM CaCl2, 0.01% w/v sodium azide) at 4°C.  Expression and purification of INF2-FL non-
CAAX, CAP1-GFP and CAP2-GFP in Expi 293-F cells (Life Tech #A14527) was described previously 
(8) and described in detail in the SI Appendix.  For recombinant -actin expression and 
purification in Expi 293-F cells, previously described methods (30, 31) were adapted, and are 
described in detail in the SI Appendix.  Protein expression and purification of INF2-Nterm, INF2 
C-term and the GST-fusion of human CAP1-Cterm from E. coli are described in (6) and (12).  
Labeling of INF2-Cterm with tetramethylrhodamine-succinimide (TMR, Molecular probes; 
C1171) previously described (6).  Labeling of CAP1- and CAP2-WH2 with fluorescein 
isothiocyanate (FITC)-maleimide (Thermo Fisher; 62245) is described in the SI Appendix. 
 
Antibodies 
CAP1 and CAP2 rabbit polyclonal against GST-human CAP1 and GST-human CAP2 produced by 
Cocalico Biologicals Inc.  Antibodies affinity purified using the GST-fusion proteins attached to 
Sulfo-link (ThermoFisher 20404) in presence of 10 mg/mL GST, and eluted in 200 mM glycine-
HCl pH 1.9, then dialyzed into PBS.  Anti-actin (mouse monoclonal, clone C4, Millipore, 
MAB1501), anti-calnexin (rabbit monoclonal，  Cell Signaling, 2679), anti-mCherry (rat 
monoclonal, invitrogen, M11217).  Anti-INF2 rabbit polyclonal was described previously (35).  
Secondary antibodies:  IRDye 680RD goat anti-mouse (LiCor 926-68070), and IRDye 800CW goat 
anti-rabbit (LiCor 926-32211). 
 
Actin biochemical assays 
Pyrene actin polymerization assay and high-speed sedimentation assay are described in detail 
in the SI Appendix.  Actin exchange onto CAP was described previously (8) and in the SI 
Appendix.  Fluorescence anisotropy measurements were described in (6) and in detail in the SI 
Appendix.  Units reported here are milli-anisotropy units.  For CAP/actin nucleotide content 
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analysis, CAP2/293A was loaded on strep-tactin beads, then incubated in G-buffer alone 
(containing 0.2 mM ATP) or in G-buffer containing the indicated actin overnight at 4˚C with end-
over-end rotation.  Beads washed with 20CV G-buffer then 20 CV K50MEHD (10mM Hepes 
pH7.4, 50mM KCl, 1mM MgCl2, 1mM EGTA, 1 mM DTT), before elution with K50MEHD 
containing 2.5mM dethiobiotin.  Samples balanced for CAP2 protein mass by Coomassie-
stained SDS-PAGE gel, then boiled 7min.  Protein removed by centrifugation at 13,000xg 5 min 
and supernatant loaded onto 1mL SourceQ followed by salt gradient (0-150mM NaCl, 10mM 
Tris pH8.0) elution.  Unexchanged samples were in K50MEHD, and were never exposed to ATP 
during purification or mock exchange.   
 
Cellular assays 
Live-cell and fixed-cell imaging methods are described in detail previously (41, 42) and in the SI 
Appendix.  Flow cytometry is described in the SI Appendix.  Quantification of CAP1, CAP2, INF2 
and actin levels from U2OS cell extracts is described in detail in the SI Appendix.  Cytosolic 
concentrations estimated using a cytoplasmic volume calculated for Cos7 cells obtained from 
(44), except for the nuclear volume which was provided by Sarah Cohen (University of North 
Carolina, Chapel Hill).   
 
 
Statistical Analysis 
Errors (standard error of the mean (except for table1, which was standard deviation)) were 
calculated using Excel (Microsoft, version 2007 or 2010).  Binding curves were fit and 
dissociation constants (Kd) were calculated using KaleidaGraph 4.5.3.  Linear standard curves 
were fit using Excel (Microsoft, version 2007 or 2010). 
 
Data Availability 
All data are available in the manuscript and supporting information. 
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Table 1 
Concentrations of CAP1, CAP2, INF2 and actin in U2OS cells. 
 
 Molecules/cell (x106) Cytoplasmic 
concentration (M) 
N 
CAP1 7.95 ± 1.23 4.21 8 
CAP2 0.444 ± 0.089 0.24 6 
INF2 0.0879 ± 0.0105 0.05 6 
Actin 196 ± 12 104.00 6 
Concentrations reflect CAP and INF2 monomers. 
  
Mu A et al  INF2 inhibition by CAP/actin complex 
 16 
Figure Legends: 
Fig. 1. 
INF2, CAP, and the bridge model of INF2 inhibition.  (A) Schematic of human INF2-nonCAAX 
(1,240 amino acids), including DID (amino acids 32-261), formin homology 1 domain (FH1, 421-
520), formin homology 2 domain (FH2, 554-940), and DAD/WH2 (971-1000).  Boundaries of the 
N-terminal construct (NT) and FH1-FH2-C (FFC) construct used in this study are also shown.  (B) 
Schematic of human CAP2 (477 amino acids), including oligomerization domain (OD, amino 
acids 1-42), helical folded domain (HFD, 43-217), proline-rich region 1 (PP1, 229-245), WH2 
motif (254-297), proline-rich region 2 (PP2, 308-323), and CARP domain (324-477).  (C) Actin 
monomers (blue, gray surfaces) bound to dimeric CARP domain of CAP1 (black, green ribbons).  
K50, K61 and K328 on actin are highlighted in red, orange and yellow, respectively.  Actin sub-
domains indicated by white letters.  N, amino-termini of CARP subunits.  Adapted from PDB 
6FM2.  Bottom:  structure rotated 90˚ to left.  (D) Bridge model of INF2 inhibition by CAP/actin, 
whereby INF2-DID interacts with CAP-WH2, while INF2-DAD interacts with acetylated actin, 
which is bound to the CARP domain of CAP. 
 
Fig. 2. 
K-to-Q mutant actins are polymerization-competent.  (A) Quantification of M amounts of actin 
in supernatant from high-speed pelleting assays.  Actins were polymerized 18 hr at 23˚C (2 M 
actin), then ultra-centrifuged to separate polymerized actin (pellet) from monomeric actin 
(supernatant).  Four conditions tested:  actin alone (-), + 20 nM INF2-FL (FL), + 20 nM INF2-FFC 
(FFC), and + 10 nM capping protein (CP).  Sample gels shown in Fig. S1C.  (B) and (C) Pyrene-
actin polymerization assays of 2 M actin alone (B) or + 20 nM INF2-FL (C).  Actin composition:  
1.9 M of the indicated actin + 0.1 M pyrene-labeled RSK actin.  (F) Time to half-maximum 
polymerization, measured from pyrene-actin curves similar to panels C-E. 
 
Fig. 3. 
-actin mutants K50Q and K61Q, when bound to CAP2, inhibit INF2-mediated actin 
polymerization in biochemical assays.  (A) Pyrene-actin polymerization assays (2 M RSK-actin, 
5% pyrene-labeled) containing 20 nM INF2-FL and 1 M of the indicated CAP/actin complex.  
(B) Concentration curves of CAP/actin inhibition of INF2-FL polymerization activity, from assays 
similar to panel B.  Polymerization activity of actin alone (black) and with INF2-FL (brown) 
shown to left of the curves.  (C) Pyrene-actin polymerization assays of actin alone (2 M RSK-
actin, 5% pyrene-labeled) or in the presence of 1 M of the indicated CAP/actin complex.  (D) 
Pyrene-actin polymerization assays (2 M RSK-actin, 5% pyrene-labeled) with 20 nM INF2-FFC 
and 1 M of the indicated CAP/actin complex.  (E) Pyrene-actin polymerization assays similar to 
those in panel D, in which varying ratios of K50Q:WT-b-actin were exchanged onto CAP2, then 
assayed for inhibition of INF2-FL.  The percentages listed represent the percent K50Q-actin in 
the exchange reaction.  Concentrations in pyrene-actin assays:  2 M RSK-actin (5% pyrene), 20 
nM INF2-FL, 1 M CAP/actin.  (F) Graph of INF2-FL activity in the presence of 1 M CAP/actin as 
a function of % K50Q-actin in exchange reactions, from data similar to those in panel H. 
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Fig. 4. 
-actin K50Q and K61Q mutants inhibit the calcium-induced actin burst in U2OS cells.  (A) 
Schematic of mammalian expression construct, co-expressing -actin (un-tagged) and mCherry.  
(B) Micrographs of calcium-induced actin burst for cells expressing four -actin constructs:  WT, 
K61Q, K50Q and K328Q.  U2OS cells were co-transfected with the -actin/mCherry expression 
plasmid along with a plasmid containing GFP-Ftractin (to label actin filaments).  Live cells were 
imaged for GFP and mCherry before and during stimulation with ionomycin (4 M in serum-
containing medium).  Micrographs at left are full-field views of GFP and mCherry.  Micrographs 
in center are zoomed views of GFP-Ftractin at three time points of ionomycin stimulation (0, 1 
and 5 min) for two cells in the field:  an mCherry-expressing cell (top) and a cell not expressing 
detectable mCherry (bottom).  At right is a differential heat map showing the ratio of the actin 
signal at 1 min to the signal at 0 min (red/yellow colors denote higher 1min:0min ratio).  Bars, 
25 m (left panels) and 10 m (zooms).  (C) Quantification of the ionomycin-induced actin burst 
for cells expressing WT -actin, K50Q -actin, K61Q -actin, and K328Q -actin, as compared to 
cells not expressing an actin/mCherry construct (untransfected).  Results are from three 
experiments, with a total of 17 (untransfected), 38 (WT), 42 (K61Q), 29 (K50Q) and 34 (K328Q) 
cells analyzed.  (G) Quantification of the CCCP-induced actin burst for cells transfected with the 
mCherry vector with no actin (Vector/CCCP, black, 61 cells), the mCherry/WT-actin vector (WT-
actin/CCCP, green, 71 cells), or the mCherry/K50Q-actin vector (K50Q-actin/CCCP, red, 72 cells).  
Mock-stimulation of mCherry/no actin-transfected cells (Vector/DMSO, blue, 40 cells) shown 
for comparison.  Results from 3 independent experiments. 
 
Fig. 5. 
CAP’s WH2 binds INF2 DID, while INF2’s DAD binds CAP/KAc-actin.  (A) Schematic of binding 
interactions measured in the following panels, showing bars for INF2 (top bar) and CAP (bottom 
bars) and a purple square for actin.  (B-F) Fluorescence anisotropy measurements using 
TAMRA-INF2-Cterm (50 nM) or FITC-CAP2-WH2 (100 nM).  (B) Interaction between INF2-Cterm 
and WT--actin (black) or K50Q--actin (blue).  (C) Interaction between CAP2-WH2 and RSK-
actin (green), WT--actin (black) or K50Q--actin (blue).  CAP1-WH2 results in SI Appendix S5B.  
(D) Interaction between INF2-Cterm and CAP/WT--actin (black) or CAP/K50Q--actin (blue) 
complex.  (E) Interaction between CAP2-WH2 and INF2-Nterm (black) or INF2-A149D-Nterm 
(blue).  CAP1-WH2 results in SI Appendix S5C.  (F) Interaction between INF2-Cterm (right) and 
INF2-Nterm (black) or INF2-A149D-Nterm (blue).  All anisotropy values in milli-anisotropy units. 
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Fig. S1.  Purified b-actin.  (A) Coomassie gel of Ni-NTA eluted actin-Tb4 construct, as well 
as rabbit muscle actin.  (B) Coomassie-stained SDS-PAGE of purified b-actin (WT, K50Q, 
K61Q and K328Q), compared to rabbit muscle actin (RSK).  1 µg protein loaded on gel.  
(C) High-speed pelleting assays testing the polymerization of actin alone or with other 
proteins.  Actin was polymerized 18 hr at 23˚C (2 µM actin), then ultra-centrifuged to 
separate polymerized actin (pellet) from monomeric actin (supernatant).  Four conditions 
tested:  actin alone (-), + 20 nM INF2-FL (FL), + 20 nM INF2-FFC (FFC), and + 10 nM 
capping protein (CP).    Standards are RSK-actin corresponding to the indicated µM values 
under pelleting assay conditions.  Gels loaded and stained differentially for supernatants 
and pellets, corresponding to higher actin levels in pellets under all conditions.  (D) Pyrene-
actin polymerization assays of 2 µM actin + 20 nM INF2-FFC.  Actin composition:  1.9 µM 
of the indicated actin + 0.1 µM pyrene-labeled RSK actin.   
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Fig. S2.  CAP2/actin complex.  (A) Coomassie-stained SDS-PAGE of purified CAP2/actin 
complexes after exchange with the indicated actins.  CAP/293A represents mock-
exchanged CAP that retains actin from HEK293 cell expression.  1 µg total protein loaded 
for each sample.  Asterisk denotes untagged CAP (CAP1 from 293 cells, see Fig. S4A,B) 
that co-purifies with CAP2-GFP. (B) Nucleotide content of CAP2/293A, as judged by 
anion-exchange chromatography.  Peaks of ATP and ADP standards shown in red 
(ADP/ATP).  Purified CAP2/293A shown in green (unexchanged), and CAP2/293A that 
had been incubated overnight in 0.2 mM ATP shown in purple (+ATP).  (C) Nucleotide 
content of CAP2/293A that has been subject to exchange with WT- or K50Q- -actin.  (D) 
Coomassie gel showing GST-CAP1-Cterm that has been incubated in G-buffer alone, or 
G-buffer containing a 5-mole excess of RSK-actin, WT- or K50Q- -actin.  Also shown is 
an RSK-actin standard at an amount that represents 50% of the expected signal if CAP is 
fully bound to actin in the experiment.  The percentage of binding to CAP1-Cterm for the 
actins tested are: RSK, 14.6%; WT, 15.1%; K50Q, 13.8%.  All lanes from the same gel 
and processed in the same manner, with intervening lanes cropped out.   
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Fig. S3.  Effects of b-actin in U2OS cells.  (A) Micrographs of calcium-induced actin burst 
for cells not expressing mCherry (untransfected) or expressing the mCherry vector without 
an accompanying actin gene (Vector).  Cells transfected with plasmid containing GFP-
Ftractin (to label actin filaments) or co-transfected with this plasmid and plasmid 
expressing mCherry.  Live cells imaged for GFP and mCherry before and during 
ionomycin stimulation (4 µM in serum-containing medium).  Left:  full-field views of GFP 
and mCherry.  Center:  zoomed views of GFP-Ftractin at three time points of ionomycin 
stimulation (0, 1 and 5 min) for two cells in the field:  an mCherry-expressing cell (top) and 
a cell not expressing detectable mCherry (bottom).  Right:  differential heat map showing 
the ratio of the actin signal at 1 min to the signal at 0 min (red/yellow colors denote higher 
1min:0min ratio).  Bars, 25 µm (left panels) and 10 µm (zooms).  (B) Graph quantifying 
the ionomycin-induced actin burst for untransfected or vector-expressing cells.  Results 
from three experiments, total of 17 (untransfected) and 17 (Vector) cells analyzed.  (C) 
Micrographs of CCCP-induced actin burst for cells expressing the mCherry vector without 
an accompanying actin gene (Vector), the mCherry/b-actin K50Q mutant (K50Q) or the 
mCherry/b-actin wild-type (WT) vector.  U2OS cells co-transfected with a plasmid 
containing GFP-Ftractin and the plasmid expressing mCherry.  Live cells imaged for GFP 
and mCherry before and during stimulation with CCCP (20 µM).  Zoomed views of actin 
are shown before stimulation (0 min), at peak stimulation (2 or 2.5 min) and after 
depolymerization (7.5 min).  Bars, 10 µm (left) and 5 µm (right). 
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Fig. S4.  Assessing effects of exogenously expressed b-actin.  (A) Western blots of flow-
sorted U2OS cells transfected with four versions of b-actin/mCherry vector (Vector = no 
b-actin).  Cells sorted by mCherry signal level (L = low mCherry, H = high mCherry, N = 
no mCherry signal).  Westerns of equal cell numbers probed for mCherry, actin, and 
calnexin (loading control).  U = untransfected control.  K328Q western is a different blot 
from others.  (B) Densitometric quantification of actin levels of blots in panel A, normalized 
to calnexin signal.  (C) Cells transfected with plasmids indicated, then fixed and stained 
with FITC-phalloidin.  Two z sections shown, one at the basal region, and one in the medial 
region.  Scale bar, 50 µm.  (D) Quantification of overall cellular GFP-F-tractin intensity 
from U2OS cells co-transfected with GFP-F-tractin plasmid and indicated actin/mCherry 
co-expression vector.  Intensity measurements taken in medial section prior to ionomycin 
stimulation (same data set as Fig. 4).  UN = untransfected with actin/mCherry vector.  
Lines represent mean intensities:  1874±982 for UN (n = 17 cells, standard deviation), 
1498±471 for vector (n = 10), 1657±685 for WT (n = 41), 2090±1155 for K50Q (n = 29), 
1379±535 for K61Q (n = 43), and 1945±1094 for K328Q (n = 27).  (E) Quantification of 
overall cellular mCherry intensity from U2OS cells co-transfected with GFP-F-tractin 
plasmid and indicated actin/mCherry co-expression vector.  UN = untransfected with 
actin/mCherry vector.  Lines represent mean intensities:  516±8.86 for UN (n = 17 cells, 
standard deviation), 871±350 for vector (n = 10), 890±267 for WT (n = 41), 607±53.8 for 
K50Q (n = 29), 1042±356 for K61Q (n = 43), and 953±381 for K328Q (n = 27).  (F) Plot of 
F-tractin intensity at peak ionomycin stimulation versus initial F-tractin intensity for cells 
co-transfected with GFP-F-tractin plasmid and WT-b-actin/mCherry co-expression 
plasmid.  Intensity measurements taken in a medial cell section (same data set as Fig. 1). 
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Fig. S5.  Binding between CAP1 WH2 and actin or INF2-DID.  (A) Alignment of WH2 
regions for CAP1 and CAP2 with other WH2 motifs of or DAD sequences (all human 
sequences).  Numbers indicate start and end amino acids.  CAP sequences represent those 
used in binding studies, Red indicates positions of the 10 most conserved positions in WH2 
motifs (1).  (B) Interaction between CAP1-WH2 (100 nM) and RSK-actin (green), WT-b-
actin (black) or K50Q-b-actin (blue) by fluorescence anisotropy.  (C) Interaction between 
CAP1-WH2 and INF2-Nterm (black) or INF2-A149D-Nterm (blue) by fluorescence 
anisotropy.  All anisotropy values in milli-anisotropy units. 
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Fig. S6.  CAP1, CAP2, INF2 and actin levels in U2OS cells.  (A) Western blots of anti-
CAP1 (left) and anti-CAP2 (right) against indicated ng amounts of purified GFP fusions.  
Arrows indicate GFP-CAP, asterisks indicate untagged CAP.  (B) Quantification of western 
band intensity for anti-CAP1 (left), anti-CAP2 (middle), and anti-INF2 (right) against 
indicated ng amounts of purified CAP1-GFP, CAP2-GFP, or GFP-INF2-CAAX, 
respectively, mixed with 1 µg U2OS cell extract (CAP1, CAP2) or 0.5 µg U2OS cell extract 
(INF2).  Arrows - CAP-GFP, asterisks - CAP from U2OS extract.  Blots – dilution series of 
purified protein, corresponding to values on graph.  (C) Quantification of western band 
intensity for indicated µg amounts of U2OS extract, blotted against anti-CAP1 (left), anti-
CAP2 (middle), and anti-INF2 (right).  Blots – dilution series of extract, corresponding to 
values on graph.  (D) Dot plots of individual concentration determinations for CAP1, CAP2, 
and INF2.  Inset - expanded Y-axis for CAP2 and INF2.   
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Supplementary Methods 
 
Protein expression and purification 
For protein expression in mammalian cells (INF2-FL non-CAAX, CAP1, CAP2, b-actin), 
3 x 106  cells/mL Expi 293-F cells (Life Tech #A14527) growing in 1L Expi 293 expression 
medium (Life Tech A1435102) transfected with 1mg DNA and 3mg sterile 25kDa linear 
PEI mixed in Opti-MEM reduced-serum medium (Life Tech 31985070).  0.5mM enhancer 
1 (Sigma # P4543) and 5mM enhancer 2 (Sigma # P1880) supplemented into the cell 
culture after 16hrs to boost protein expression.  Proteins expressed at 37 °C, 8% CO2 with 
shaking at 125 rpm for 2 days (INF2) or 3 days (CAP1, CAP2, b-actin).  
 
For strep-tagged protein purification from Expi 293 cells, all steps were performed at 4°C 
or on ice. Cells pelleted at 300xg for 15min, and pellet resuspended in 45mL EB1 (100mM 
Hepes pH7.4, 500mM NaCl2, 5mM EDTA, 1mM DTT, 1% v/v TritonX-100, protease 
inhibitors (2μg/mL leupeptin, 10μg/mL aprotinin, 2μg/mL pepstatin A, 1μg/mL calpeptin, 
1μg/mL calpain inhibitor 1, 1mM bezamidine), 1:1000 dilution universal nuclease 
(ThermoFisher)) per 5mL pellet followed by 30min end-over-end incubation. Cell debris 
removed by ultracentrifugation at 185,000xg for 1 hr (Ti45 rotor, Beckman), and 
supernatant blocked with avidin (20μg/mL Sigma-Aldrich 189725) then applied to Strep-
Tactin Superflow resin (2-1206-025; IBA, Göttingen, Germany) equilibrated in EB by 
gravity flow.  After wash with WB (10mM Hepes pH7.4, 150mM NaCl2, 1mM EDTA, 
1mM DTT), column was either:  1) treated with HRV3C protease in WB (1:50 
enzyme:substrate molar ratio) 16hrs at 4°C followed by 3 column volume WB wash; or 2) 
eluted with 10mM Hepes pH7.4, 150mM NaCl, 1mM EDTA, 1mM DTT, 2.5mM 
desthiobiotin. Protein concentrated with 30 kDa MWCO Amicon Ultra-15 (Millipore) 
before gel filtration through Superdex 200 16/60 (GE Bioscience) in 10mM Hepes pH7.4, 
50mM KCl, 1mM MgCl2, 1mM EGTA, 1mM DTT. Protein further concentrated to >10 
µM before aliquoted, frozen in liquid nitrogen, and stored at -80˚C.  N.B. – in all cases, 
Hepes pH given is pH at 23˚C. 
 
For recombinant b-actin, all steps at 4°C or on ice.  Cells pelleted at 300xg for 15min, and 
pellet resuspended in 45mL EB2 (1M Tris pH7.5 at 4C, 600mM NaCl, 0.5mM MgCl2, 
0.5mM Na2ATP, 1mM DTT, 4% TritonX-100, 1mg/mL Tween, protease inhibitors, 
1:1000 dilution universal nuclease) per 5mL pellet followed by 2hrs end-over-end 
incubation. Cell debris removed by ultracentrifugation at 185,000xg 1 hr (Ti45 rotor), and 
supernatant dialyzed into 10mM Hepes pH7.4 at RT, 0.25mM CaCl2, 300mM NaCl, 7mM 
β-ME. 0.05mM ATP then applied to Ni-NTA agarose resin (ThermoFisher #90115) by 
gravity flow.  After wash with 10mM Hepes pH7.4 at RT, 0.25mM CaCl2, 300mM NaCl, 
7mM β-ME. 0.05mM ATP, 10mM imidazole, protein eluted with 10mM Hepes pH7.4 at 
RT, 0.25mM CaCl2, 300mM NaCl, 7mM β-ME. 0.25mM ATP and 1ug/mL Leupeptin, 
100mM imidazole to obtain β-actin-thymosinβ4-6xHis fusion. Protein dialyzed into G-
buffer overnight and chymotrypsin digested (1:80-1:150 w/w chymotrypsin:actin, tested 
empirically for each preparation(Sigma C3142)) 1hr on ice.  Reaction quenched by 2.5mM 
Diisopropylfluorophosphate, 2μg/mL leupeptin and 10μg/mL aprotinin.  Cleaved full-
length β-actin separated from other digestion products by SourceQ (GE Biosciences) 
eluting with 0-300 mM NaCl gradient (5mM Tris pH8.26 at 4C, 0.2mM CaCl2, 3mM 
NaN3. 0.5mM DTT, 1ug/mL leupeptin).  0.2mM ATP immediately added to SourceQ 
fractions, then dialyzed into 10mM Hepes pH7.4, 50mM KCl, 1mM MgCl2, 1mM EGTA, 
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2 mM Tris-HCl pH 8, 0.5 mM DTT, 0.2 mM ATP, 0.1 mM CaCl2, 0.01% w/v sodium 
azide overnight.  Polymerized actin pelleted by ultracentrifugation 1 hr at 207,871xg, 4˚C 
(Ti70 rotor, Beckman) and resuspended with G-buffer.  Filaments sheared through 27G 
needle, and dialyzed in G-buffer overnight.  Depolymerized actin ultracentrifuged at 
386,985xg (Ti70.1 rotor, Beckman) and supernatant gel-filtered on Superdex 75 16/60 (GE 
Biosciences) in G-buffer.  Purified actin stored in G-buffer at 4°C under dialysis, changing 
buffer weekly. 
 
For protein expression from E. coli (INF2-DID, INF2-Cterm, full-length CAP1, full-length 
CAP2, CAP1-WH2 and CAP2-WH2), Rosetta2 nonDE3 cells (Millipore/Sigma) 
transformed and grown at 37˚C in 1L Terrific Broth media containing 50μg/mL ampicillin 
and 34μg/mL chloramphenicol.  500μM IPTG added when OD600 reached 2, followed by 
overnight at 20˚C. All purification steps performed at 4°C or on ice. Cells pelleted at 600xg 
15min, and pellet resuspended in 100mL EB3 (50 mM Tris pH 8, 500mM NaCl, 5mM 
EDTA, 1mM DTT, protease inhibitors, 1:1000 dilution universal nuclease) per 10g pellet. 
Cells disrupted using a Microfluidizer at 12000psi and debris removed by 
ultracentrifugation at 185,000xg for 1 hr (Ti45 rotor).  Supernatant applied to Glutathione 
Sepharose resin (ThermoFisher #25236).  After wash with 10 mM Tris-HCl pH 8, 250 mM 
NaCl, 1 mM EDTA, 1 mM DTT, 0.05% thesit, column was either:  1) treated with 0.5µM 
TEV protease in 10 mM Tris-HCl pH 8, 250 mM NaCl, 1 mM MgCl2, 1 mM EGTA, 1 
mM DTT, 0.05% thesit overnight at 4°C to obtain untagged protein (INF2-Cterm); or 2) 
eluted with 10 mM Tris-HCl pH 8, 250 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.05% thesit, 
10mM reduced glutathione (CAP1, CAP2, CAP1-WH2 and CAP2-WH2).  Protein gel 
filtered through Superdex 75 16/60 (GE Bioscience) in 10mM Hepes pH7.4, 50mM KCl, 
1mM MgCl2, 1mM EGTA, 1mM DTT.   
 
For protein expression from E. coli of GST-fusions of CAP1-WH2 and CAP2-WH2 are, 
Rosetta2 nonDE3 cells (Millipore/Sigma) transformed and grown at 37˚C in 1L Terrific 
Broth media containing 50μg/mL ampicillin and 34μg/mL chloramphenicol.  500μM IPTG 
added when OD600 reached 2, followed by overnight at 20˚C. All purification steps 
performed at 4°C or on ice. Cells pelleted at 600xg 15min, and pellet resuspended in 
100mL EB3 (50 mM Tris pH 8, 500mM NaCl, 5mM EDTA, 1mM DTT, protease 
inhibitors, 1:1000 dilution universal nuclease) per 10g pellet. Cells disrupted using a 
Microfluidizer at 12000psi and debris removed by ultracentrifugation at 185,000xg for 1 
hr (Ti45 rotor).  Supernatant applied to Glutathione Sepharose resin (ThermoFisher 
#25236).  After wash with 10 mM Tris-HCl pH 8, 250 mM NaCl, 1 mM EDTA, 1 mM 
DTT, 0.05% thesit, column was either:  1) treated with 0.5µM TEV protease in 10 mM 
Tris-HCl pH 8, 250 mM NaCl, 1 mM MgCl2, 1 mM EGTA, 1 mM DTT, 0.05% thesit 
overnight at 4°C to obtain untagged protein (INF2-Cterm); or 2) eluted with 10 mM Tris-
HCl pH 8, 250 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.05% thesit, 10mM reduced 
glutathione (CAP1, CAP2, CAP1-WH2 and CAP2-WH2).  Protein gel filtered through 
Superdex 75 16/60 (GE Bioscience) in 10mM Hepes pH7.4, 50mM KCl, 1mM MgCl2, 
1mM EGTA, 1mM DTT.   
 
Protein labeling 
Labeling of CAP1- and CAP2-WH2, GST-CAP1-WH2 and GST-CAP2-WH2 dialyzed 
into 20mM Hepes pH 7.4 at RT, 100mM KCl, 1mM TCEP at 4°C overnight, then incubated 
with 20-fold molar excess fluorescein isothiocyanate (FITC)-maleimide (Thermo Fisher; 
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62245) at 4°C overnight.  Free dye removed by gel filtration using Superdex200 10/30 (GE 
Biosciences) in 10mM Hepes pH7.4, 50mM KCl, 1mM MgCl2, 1mM EGTA, 1mM DTT.  
Protein reapplied to Glutathione Sepharose, then treated with HRV3C protease to elute the 
FITC-labeled WH2 peptide.  The fragments containing HRV3C and 8xHis-tag were 
removed by passing eluted FITC-WH2 peptide through Ni-NTA.  Final protein 
concentration determined by Bradford (BioRad) and FITC concentration using extinction 
coefficient 72,000 M-1 cm-1 at 495 nm. Calculated ratio of FITC:WH2 0.92 (CAP1-WH2) 
and 0.89 (CAP2-WH2). 
 
Pyrene actin polymerization assay 
Rabbit skeletal muscle actin or recombinant β-actin in G-buffer (6 μM actin, 5% pyrene) 
converted to Mg2+ salt by addition of EGTA and MgCl2 (to 1 and 0.1 mM, respectively) 
for 2 min at 23°C immediately prior to polymerization. Polymerization induced by 2 
volumes of 1.5xpolymerization buffer (75mM KCl, 1.5mM MgCl2, 1.5mM EGTA, 15 mM 
Hepes pH 7.4, 2mM DTT, 2 mM Tris-HCl, 0.2 mM ATP, 0.1 mMCaCl2, and 0.01% w/v 
NaN3) containing other proteins. Pyrene fluorescence (365/410 nm) monitored in a 96-well 
fluorescence plate reader (Infinite M1000; Tecan, Mannedorf, Switzerland) within 1min of 
inducing polymerization.  Slope of curve at ½ max is plotted to represent polymerization 
activity. 
 
High-speed sedimentation assay 
2 μM rabbit muscle actin or β-actin was polymerized alone, or with 20nM INF2-FL, 20nM 
INF2-FFC or 10nM capping protein in 1x polymerization buffer at room temperature 
overnight.  Samples centrifuged at 80,000 rpm 20 min 4°C in TLA-100.1 rotor (Beckman). 
Supernatant carefully removed, pellets washed briefly and gently with polymerization 
buffer before resuspension in SDS-PAGE buffer.  Samples resolved by SDS–PAGE. Gels 
stained either with Colloidal Blue Staining (Invitrogen LC6025) (supernatant) or 
Coomassie Blue Staining (BioRad 161-0400) (pellet), and band intensity analyzed using 
ImageJ software.  Microgram amount of actin was quantified from rabbit muscle actin 
standards. 
 
Actin exchange onto column-bound CAP 
CAP2-GFP-2xstrep (also containing bound actin from 293 cells) was immobilized on 
strep-tactin beads (1 µM CAP2 monomer), then washed with G-buffer. The indicated 
species of actin (5 µM, in G-buffer) added and incubated with beads at 4°C with end-over-
end rotation for 12hrs. Beads washed with 20 column volumes G-buffer.  CAP2-GFP was 
removed from beads by either:  eluting with G-buffer containing 2.5mM dethiobiotin, or 
2) cleavage from beads by HRV3C protease (1:50, overnight at 4˚C).  Concentration of 
CAP2-GFP was determined by densitometry (ImageJ) using actin as standards.   For GST-
CAP1-Cterm purified from E. coli (not containing bound actin) same procedure used with 
glutathione-sepharose resin and eluting with G-buffer containing 10mM reduced 
glutathione.  Percentage of actin full binding was determined by densitometry (ImageJ) 
using RSK-actin as standard.  
 
Fluorescence anisotropy 
For measurements of CAP-WH2 or INF2-Cterm with actin monomer, fluorescent proteins 
diluted to 200 nM (fluorescein-labeled CAP1-WH2 or CAP2-WH2) or 100 nM (TMR-
INF2-Cterm) in 2× polymerization buffer containing 0.02% thesit. Stock of actin 
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monomers mixed with 1.5× molar excess of latrunculin A (EMD Millipore, 428021) 
prepared in G-buffer, from which dilutions were further made.  Equal volumes of FITC-
CAP-WH2 and actin/LatA were incubated at least 1 hr in dark at 23˚C.  For measurement 
of CAP-WH2 or INF2-Cterm with INF2-DID, fluorescent proteins diluted as above, and a 
stock of INF2-DID was prepared in 1xK50MEH/GT from which further dilutions were 
made.  Equal volumes of FITC-CAP-WH2 and INF2-DID were mixed together and 
incubated overnight in dark at 23˚C before fluorescence readings.  FITC fluorescence 
(470/525 nm) or TMR fluorescence (530/585 nm) anisotropy monitored in a 96-well 
fluorescence plate reader (Infinite M1000; Tecan, Mannedorf, Switzerland) and reported 
as milli-anisotropy units. 
 
Quantification of protein cellular concentration 
Quantitative western blotting was used to determine endogenous CAP1, CAP2, and INF2 
concentration in U2OS cells, and Colloidal Blue Staining (Invitrogen LC6025) was used 
to determine endogenous actin concentration in U2OS cells. To prepare cell extract, cells 
growing logarithmically were trypsinized, washed in phosphate-buffered saline (PBS), 
then resuspended in PBS, and quantified for cell number (TC20, BioRad) and protein 
concentration (Bradford). Cellular protein was calculated at 0.37±0.045 ng/cell, similar to 
values obtained for other adherent cell types growing in monolayer (55). Protein extracted 
in 9 volumes of 4% SDS, 10 mM DTT followed by immediate boiling for 5 min, followed 
by 1 min in 23˚C water bath.  N-ethylmaleimide (Sigma-Aldrich) added to 30 mM. Extract 
mixed 1:1 with 2xDB (250 mM Tris-HCl, pH 6.8, 2 mM EDTA, 20% glycerol, 0.8% SDS, 
0.02% bromophenol blue, 1 M NaCl, 4 M urea) and further diluted with 1xDB to obtain 
desired concentrations. Linear concentration ranges determined for protein of interest for 
both the purified standard protein and the protein from extract.  For the concentration 
determination by western (CAP1, CAP2 and INF2), purified GFP-fusion standard proteins 
were included as internal standards in  fixed concentration of extract in the linear detection 
range.  Proteins resolved by SDS–PAGE and detected by western blot using an Odyssey 
CLx Imager (Li-Cor).  Band densities quantified using ImageJ (NIH). Both bands of the 
doublet CAP1-GFP and CAP2-GFP included in quantification.  For actin, similar 
techniques were used as in past studies (43).  Briefly, 4-10 µg total U2OS protein were 
compared with standard curve of RSK-actin (50-300 ng) by SDS-PAGE followed by 
colloidal Coomassie staining.  Mean and standard deviation of eight (CAP1) or six (CAP2, 
INF2, actin) independent data points reported. 
Cytosolic concentrations estimated using a cytoplasmic volume calculated for Cos7 cells 
by subtracting volumes of nucleus (0.902 pL), endoplasmic reticulum (1.538 pL), 
peroxisome (0.186 pL), mitochondria (0.179 pL), lysosome (0.089 pL) and Golgi (0.042 
pL) from total cell volume (6.074 pL) obtained from (2), except for the nuclear volume 
which was provided by Sarah Cohen (University of North Carolina, Chapel Hill) from 
lattice lightsheet microscopy images.  The cytoplasmic volume obtained (3.138 pL) is 
similar to that obtain previously for NIH 3T3 cells (2.26 pL) by different methods (55).  
Cytoplasmic concentrations should be taken as estimates for two reasons:  1) we do not 
have a cytoplasmic volume for U2OS cells; and 2) we have not determined whether the 
proteins examined here reside solely in cytoplasm. 
 
Flow cytometry 
U2OS cells co-expressing β-actin and mCherry were trypsinzed and washed into cold PBS.  
A Sony SH800 was used to sort untransfected cells (< 200 RFU), low mCherry expressing 
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cells (200-2000 RFU), and high mCherry expressing cells (>2000 RFU) using a 100 μm 
nozzle.  Data collected using Sony Cell Sorter Software v 2.1.5.  20,000 cells collected for 
each condition and pelleted by centrifugation at 300xg for 5 min.  Pellet washed with PBS 
then resuspended in 50 μL PBS.  Cells were mixed 1:1 with 2xDB and analyzed by western 
blotting.  Actin signal from each sample was normalized against calnexin signal. 
 
Live cell imaging and analysis 
Wild-type human osteosarcoma U2OS cells (American Type Culture Collection HTB96) 
grown in DMEM (Invitrogen) with 10% calf serum (Atlanta Biologicals).  Cells tested 
every 6 months for mycoplasma using LookOut PCR detection kit (Sigma-Aldrich).  Cells 
seeded at 4x105 cells per well in 6-well dish ~16 hours prior to transfection.  Plasmid 
transfections performed in OPTI-MEM media (Invitrogen) with 2 μL Lipofectamine 2000 
(Invitrogen), 400 ng GFP-Ftractin, and/or 2 µg β-actin/mCherry per well for 6 hours, 
followed by trypsinization and re-plating onto glass bottom MatTek dishes (P35G-1.5-14-
C) at ~2x105 cells per well. Cells imaged in DMEM (GIBCO, #21063-029 with 4.5g/L D-
Glucose, L-Glutamine and 25Mm HEPES) supplemented with 10% NCS (HyClone, 
#SH30118.03) ~16-24 hours after transfection.  Cells treated with 4 µM ionomycin (Sigma 
Aldrich I0634, from a 2 mM stock in DMSO), 20 µM Carbonyl cyanide 3-
chlorophenylhydrazone (CCCP) (Sigma-Aldrich, C2759, from a 100 mM stock in DMSO), 
or same volume of DMSO (Invitrogen, D12345) at ~1 min after commencement of 
imaging, and imaging continued for 5-10 min (ionomycin) or 15~20min (CCCP) . Medium 
pre-equilibrated for temp and CO2 content before use.  Imaging conducted on a Dragonfly 
302 spinning disk confocal (Andor Technology Inc, Belfast UK) on a Nikon Ti-E base and 
equipped with an iXon Ultra 888 EMCCD camera, and a Tokai Hit stage-top incubator.  
Lasers:  solid state 405 smart diode 100 mW, solid state 488 OPSL smart laser 50 mW, 
solid state 560 OPSL smart laser 50 mW, solid state 637 OPSL smart laser 140 mW.  
Objective:  100x 1.4 NA CFI Plan Apo (Nikon).  Images acquired using Fusion software 
(Andor).  Imaging conducted in a medial region (approximately 2 μm above the basal 
surface) of cells expressing low level of mCherry,. Movies analyzed in blinded manner, 
with one individual coding movies, and another analyzing.  Mean fluorescence calculated 
for each cell using ImageJ (NIH). Fluorescence values for each time point after drug 
treatment (F) were normalized by the average initial fluorescence (first 5-6 frames prior to 
stimulation-F0) and plotted against time as F/F0. 
 
Fix cell imaging 
Cells transfected with β-actin/mCherry and split onto MatTek dishes in same way as for 
live imaging. Cells fixed with 4% paraformaldehyde (Electron Microscopy Sciences Inc) 
in PBS 20min at 23˚C. After washing with PBS, cells permeabilized on ice with 0.25% 
Triton X-100 in PBS 15min. Cells washed with PBS prior to blocking with 10% calf serum 
in PBS for 1hr at 23˚C. Actin stained with 50 μg/mL FITC-phalloidin (Sigma-Aldrich) 1hr, 
and DNA stained with 0.1mg/L w/v DAPI (Calbiochem 268298) 10min at 23˚C in dark 
followed by PBS wash.  Cells imaged in PBS using Dragonfly confocal with Zyla 4.2 
Mpixel sCMOS camera, and z stacks with 0.2 μm stepsize taken.  Images from ventral and 
medial z planes used.   
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